News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
he US FDA has issued six observations pursuant to the completion of the audit.
The audit is part of the agency's inspection for three product applications filed and slated to be manufactured at this site.
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
ExoBrite antibody conjugates are validated and optimized for bright and specific detection of exosome markers
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
The company plans to execute both these tenders at their API manufacturing unit located at Savli, Gujarat, India.
MINYM can be safely used by patients above 9 years of age.
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
Subscribe To Our Newsletter & Stay Updated
